Pharmacokinetics and Dose Proportionality Study of a Novel Antiparkinsonian Agent, a 1<i>H</i>-1,2,4-Triazol-3-ylthio-conjugate of Prottremine

Pharmacokinetics and Dose Proportionality Study of a Novel Antiparkinsonian Agent, a 1<i>H</i>-1,2,4-Triazol-3-ylthio-conjugate of Prottremine

The novel antiparkinsonian agent PA-96 is the focus of our research. PA-96 supported the survival of cultured naïve dopamine neurons, alleviated motor deficits in MPTP and haloperidol-based mice models of Parkinson’s disease, and increased the density of tyrosine hydroxylase positive neurons and dop...

Full description

Saved in:
Bibliographic Details
Main Authors: Daria S. Gorina, Anastasiya V. Lastovka, Artem D. Rogachev, Alexandra V. Podturkina, Alla V. Pavlova, Oleg V. Ardashov, Nikolai S. Li-Zhulanov, Tatyana G. Tolstikova, Konstantin P. Volcho, Nariman F. Salakhutdinov
Format: Article
Language:English
Published: MDPI AG 2024-09-01
Series:Molecules
Subjects:
Parkinson’s disease
LC–MS/MS
validation
pharmacokinetic
dose proportionality
bioavailability
Online Access:https://www.mdpi.com/1420-3049/29/18/4498
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items